Alembic Pharmaceuticals Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015' that Alembic Pharmaceuticals Inc., wholly owned subsidiary of Alembic Pharmaceuticals Limited has acquired Utility Therapeutics Ltd.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharmaceuticals, through its wholly owned US subsidiary Alembic Pharmaceuticals Inc., has acquired 100% of Utility Therapeutics Ltd, a US-based pharmaceutical product development company. Utility Therapeutics owns 'Pivya', an FDA-approved drug for uncomplicated urinary tract infections (UTIs), and 'MEC', a product in development for complicated UTIs. The acquisition is being done for cash consideration of approximately $12 million, paid in a staggered manner tied to milestones, plus a share of future profits. The deal is expected to close in about 30 days and is not a related party transaction.
This acquisition gives Alembic Pharmaceuticals a ready-made USFDA-approved product (Pivya) and a pipeline asset (MEC) to commercialize directly in the US market, strengthening its US presence. The deal size is modest (~$12 million) and is milestone-linked, limiting upfront cash outflow. For shareholders, this is a strategic, low-risk entry into the US branded UTI therapy segment, though financial impact will depend on Pivya's commercial uptake.